2025 Q3 -tulosraportti
86 päivää sitten54 min
3,75 DKK/osake
Viimeisin osinko
3,15%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 432 651
Myynti
Määrä
2 429 737
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 125 | - | - | ||
| 689 | - | - | ||
| 16 | - | - | ||
| 228 | - | - | ||
| 449 | - | - |
Ylin
377,65VWAP
Alin
366,45VaihtoMäärä
2 264,2 6 104 675
VWAP
Ylin
377,65Alin
366,45VaihtoMäärä
2 264,2 6 104 675
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2. 5 päivää |
| Menneet tapahtumat | ||
|---|---|---|
| Ylimääräinen yhtiökokous 2025 | 14.11.2025 | |
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| Vuosittainen yhtiökokous 2025 | 27.3.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·4 t sittenIs Novo in comeback mode? +13,6% YTD, driven by strong US launch of oral Wegovy (18.000+ prescriptions in the first full week). The share price is still significantly below 2024 peaks after a difficult 2025 with tougher GLP-1 competition. Expectations for FY2025 according to analysts: Revenue +8–11% (ccy), EBIT +4–7% → lower baseline after guidance downgrades. Investor bear case peaked after Q3 guidance cut in Nov.; 2026 starts more constructively and with bull signals. First mover advantage through early Wegovy pill uptake helps Novo win back US-share from Eli Lilly. What is important to focus on in their 2026 guidance....especially pricing & insurance coverage for the pill format. The market factors in a slight drop in 2026 sales, but several (incl. undersigned) see upside potential if pill sales scale better than expected. 4. feb. will be a re-rating test: If pill momentum + pricing/coverage holds, current consensus and narrative could be FAR too conservative.
·10 min sittenFind it hard to see why we should go much further down before we test resistance 400 again ? It seems that NN recently has increasingly developed into a “play stock” for American hedge funds? The stock has been driven down by fear of the earnings report, and hedge funds are very good at planting fear in small private investors. I am afraid that a slightly more subdued price development in both directions will be determined by whether NN will announce a small share buyback program 4 Feb.
·6 t sittenBreak above EMA200 on daily chart rejected initially. NN will need at least one more attempt to reverse the short-term trend.
·10 t sitten · MuokattuIt's easy to get hung up on stocks one is or has been invested in for a long time. But - whether one has a loss or a gain - it's where one believes the price will go from today that counts. And there are other stocks than NOVO. Quite a few of them are guaranteed to be better to bet on, when it comes to risk and opportunities for profit. At least in the short- or medium term. Better to use the money on other stocks in the meantime.·3 t sittenKim19: I also believe that Novo will be a winner again. So I will still keep an eye on them.
·18 t sittenI don't really care if the price rises or falls right now. I'm looking at at least a 5-year perspective : Novo Nordisk is extremely strong, not only here and now, but also in the long run. Several structural and strategic factors indicate that the share price has good conditions for a stable, gradual increase over the next five years. 1. Healthcare megatrends speak Novo's language The incidence of diabetes and obesity is rising globally, driven by demographics, urbanization, and lifestyle. Novo Nordisk is a world leader precisely in these diseases and is positioned where demand is growing fastest. 2. Strong pipeline and continuous innovation Novo has repeatedly shown the ability to improve existing treatments and develop new ones. This provides both longer product life cycles and the opportunity to expand indications, an important driver for long-term growth. 3. Scalable business with high earnings The company has a proven ability to translate growth into solid margins and strong cash flow. This allows for investments, acquisitions, share buybacks, and stable dividends, all supporting the share price. 4. Global reach and strong brand Novo Nordisk is not dependent on one market. Its global presence reduces risk and provides access to growth in both mature and new healthcare markets. 5. Long-term management and clear strategy The company is known for disciplined capital allocation and long-term thinking. This gives investors confidence, and confidence is often an underestimated factor behind stable price increases. Overall, Novo Nordisk is an example of a company where long-term societal trends, strong innovation, and a solid business model are moving in the same direction. This does not make the stock risk-free , but it makes it structurally interesting for many years to come.·12 t sitten · MuokattuRight now there are better stocks to bet on, in that respect. Will keep an eye on NOVO - but mostly out of curiosity, since I have been heavily invested in them. They are no longer special to me. Woke up from the "addiction" and see better opportunities in other companies.. I see no logic in you being indifferent to the price here and now. Your money can be used for something good, until NOVO is again a company to invest in. No reason to sink with the ship and potentially spend a lot of time at the bottom in the meantime.
·3 t sittenYou are absolutely right. If I had not remained heavily invested in Novo after the big downturn, I could have used my money on defense stocks and NKT so. I sold off far too early, that could have reduced my loss on Novo instead of waiting for an upturn that doesn't really seem to be happening in the short term.
·19 t sittenWill we close in the green today? 😁
·17 t sittenThanks for your reply. I started here a few days ago so I didn't quite realize it kept running😏·17 t sittenRead along and separate the wheat from the chaff – then the rest is up to you 😉
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
86 päivää sitten54 min
3,75 DKK/osake
Viimeisin osinko
3,15%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·4 t sittenIs Novo in comeback mode? +13,6% YTD, driven by strong US launch of oral Wegovy (18.000+ prescriptions in the first full week). The share price is still significantly below 2024 peaks after a difficult 2025 with tougher GLP-1 competition. Expectations for FY2025 according to analysts: Revenue +8–11% (ccy), EBIT +4–7% → lower baseline after guidance downgrades. Investor bear case peaked after Q3 guidance cut in Nov.; 2026 starts more constructively and with bull signals. First mover advantage through early Wegovy pill uptake helps Novo win back US-share from Eli Lilly. What is important to focus on in their 2026 guidance....especially pricing & insurance coverage for the pill format. The market factors in a slight drop in 2026 sales, but several (incl. undersigned) see upside potential if pill sales scale better than expected. 4. feb. will be a re-rating test: If pill momentum + pricing/coverage holds, current consensus and narrative could be FAR too conservative.·10 min sittenFind it hard to see why we should go much further down before we test resistance 400 again ? It seems that NN recently has increasingly developed into a “play stock” for American hedge funds? The stock has been driven down by fear of the earnings report, and hedge funds are very good at planting fear in small private investors. I am afraid that a slightly more subdued price development in both directions will be determined by whether NN will announce a small share buyback program 4 Feb.
- ·6 t sittenBreak above EMA200 on daily chart rejected initially. NN will need at least one more attempt to reverse the short-term trend.
- ·10 t sitten · MuokattuIt's easy to get hung up on stocks one is or has been invested in for a long time. But - whether one has a loss or a gain - it's where one believes the price will go from today that counts. And there are other stocks than NOVO. Quite a few of them are guaranteed to be better to bet on, when it comes to risk and opportunities for profit. At least in the short- or medium term. Better to use the money on other stocks in the meantime.·3 t sittenKim19: I also believe that Novo will be a winner again. So I will still keep an eye on them.
- ·18 t sittenI don't really care if the price rises or falls right now. I'm looking at at least a 5-year perspective : Novo Nordisk is extremely strong, not only here and now, but also in the long run. Several structural and strategic factors indicate that the share price has good conditions for a stable, gradual increase over the next five years. 1. Healthcare megatrends speak Novo's language The incidence of diabetes and obesity is rising globally, driven by demographics, urbanization, and lifestyle. Novo Nordisk is a world leader precisely in these diseases and is positioned where demand is growing fastest. 2. Strong pipeline and continuous innovation Novo has repeatedly shown the ability to improve existing treatments and develop new ones. This provides both longer product life cycles and the opportunity to expand indications, an important driver for long-term growth. 3. Scalable business with high earnings The company has a proven ability to translate growth into solid margins and strong cash flow. This allows for investments, acquisitions, share buybacks, and stable dividends, all supporting the share price. 4. Global reach and strong brand Novo Nordisk is not dependent on one market. Its global presence reduces risk and provides access to growth in both mature and new healthcare markets. 5. Long-term management and clear strategy The company is known for disciplined capital allocation and long-term thinking. This gives investors confidence, and confidence is often an underestimated factor behind stable price increases. Overall, Novo Nordisk is an example of a company where long-term societal trends, strong innovation, and a solid business model are moving in the same direction. This does not make the stock risk-free , but it makes it structurally interesting for many years to come.·12 t sitten · MuokattuRight now there are better stocks to bet on, in that respect. Will keep an eye on NOVO - but mostly out of curiosity, since I have been heavily invested in them. They are no longer special to me. Woke up from the "addiction" and see better opportunities in other companies.. I see no logic in you being indifferent to the price here and now. Your money can be used for something good, until NOVO is again a company to invest in. No reason to sink with the ship and potentially spend a lot of time at the bottom in the meantime.·3 t sittenYou are absolutely right. If I had not remained heavily invested in Novo after the big downturn, I could have used my money on defense stocks and NKT so. I sold off far too early, that could have reduced my loss on Novo instead of waiting for an upturn that doesn't really seem to be happening in the short term.
- ·19 t sittenWill we close in the green today? 😁·17 t sittenThanks for your reply. I started here a few days ago so I didn't quite realize it kept running😏·17 t sittenRead along and separate the wheat from the chaff – then the rest is up to you 😉
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 432 651
Myynti
Määrä
2 429 737
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 125 | - | - | ||
| 689 | - | - | ||
| 16 | - | - | ||
| 228 | - | - | ||
| 449 | - | - |
Ylin
377,65VWAP
Alin
366,45VaihtoMäärä
2 264,2 6 104 675
VWAP
Ylin
377,65Alin
366,45VaihtoMäärä
2 264,2 6 104 675
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2. 5 päivää |
| Menneet tapahtumat | ||
|---|---|---|
| Ylimääräinen yhtiökokous 2025 | 14.11.2025 | |
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| Vuosittainen yhtiökokous 2025 | 27.3.2025 |
2025 Q3 -tulosraportti
86 päivää sitten54 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2. 5 päivää |
| Menneet tapahtumat | ||
|---|---|---|
| Ylimääräinen yhtiökokous 2025 | 14.11.2025 | |
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| Vuosittainen yhtiökokous 2025 | 27.3.2025 |
3,75 DKK/osake
Viimeisin osinko
3,15%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·4 t sittenIs Novo in comeback mode? +13,6% YTD, driven by strong US launch of oral Wegovy (18.000+ prescriptions in the first full week). The share price is still significantly below 2024 peaks after a difficult 2025 with tougher GLP-1 competition. Expectations for FY2025 according to analysts: Revenue +8–11% (ccy), EBIT +4–7% → lower baseline after guidance downgrades. Investor bear case peaked after Q3 guidance cut in Nov.; 2026 starts more constructively and with bull signals. First mover advantage through early Wegovy pill uptake helps Novo win back US-share from Eli Lilly. What is important to focus on in their 2026 guidance....especially pricing & insurance coverage for the pill format. The market factors in a slight drop in 2026 sales, but several (incl. undersigned) see upside potential if pill sales scale better than expected. 4. feb. will be a re-rating test: If pill momentum + pricing/coverage holds, current consensus and narrative could be FAR too conservative.·10 min sittenFind it hard to see why we should go much further down before we test resistance 400 again ? It seems that NN recently has increasingly developed into a “play stock” for American hedge funds? The stock has been driven down by fear of the earnings report, and hedge funds are very good at planting fear in small private investors. I am afraid that a slightly more subdued price development in both directions will be determined by whether NN will announce a small share buyback program 4 Feb.
- ·6 t sittenBreak above EMA200 on daily chart rejected initially. NN will need at least one more attempt to reverse the short-term trend.
- ·10 t sitten · MuokattuIt's easy to get hung up on stocks one is or has been invested in for a long time. But - whether one has a loss or a gain - it's where one believes the price will go from today that counts. And there are other stocks than NOVO. Quite a few of them are guaranteed to be better to bet on, when it comes to risk and opportunities for profit. At least in the short- or medium term. Better to use the money on other stocks in the meantime.·3 t sittenKim19: I also believe that Novo will be a winner again. So I will still keep an eye on them.
- ·18 t sittenI don't really care if the price rises or falls right now. I'm looking at at least a 5-year perspective : Novo Nordisk is extremely strong, not only here and now, but also in the long run. Several structural and strategic factors indicate that the share price has good conditions for a stable, gradual increase over the next five years. 1. Healthcare megatrends speak Novo's language The incidence of diabetes and obesity is rising globally, driven by demographics, urbanization, and lifestyle. Novo Nordisk is a world leader precisely in these diseases and is positioned where demand is growing fastest. 2. Strong pipeline and continuous innovation Novo has repeatedly shown the ability to improve existing treatments and develop new ones. This provides both longer product life cycles and the opportunity to expand indications, an important driver for long-term growth. 3. Scalable business with high earnings The company has a proven ability to translate growth into solid margins and strong cash flow. This allows for investments, acquisitions, share buybacks, and stable dividends, all supporting the share price. 4. Global reach and strong brand Novo Nordisk is not dependent on one market. Its global presence reduces risk and provides access to growth in both mature and new healthcare markets. 5. Long-term management and clear strategy The company is known for disciplined capital allocation and long-term thinking. This gives investors confidence, and confidence is often an underestimated factor behind stable price increases. Overall, Novo Nordisk is an example of a company where long-term societal trends, strong innovation, and a solid business model are moving in the same direction. This does not make the stock risk-free , but it makes it structurally interesting for many years to come.·12 t sitten · MuokattuRight now there are better stocks to bet on, in that respect. Will keep an eye on NOVO - but mostly out of curiosity, since I have been heavily invested in them. They are no longer special to me. Woke up from the "addiction" and see better opportunities in other companies.. I see no logic in you being indifferent to the price here and now. Your money can be used for something good, until NOVO is again a company to invest in. No reason to sink with the ship and potentially spend a lot of time at the bottom in the meantime.·3 t sittenYou are absolutely right. If I had not remained heavily invested in Novo after the big downturn, I could have used my money on defense stocks and NKT so. I sold off far too early, that could have reduced my loss on Novo instead of waiting for an upturn that doesn't really seem to be happening in the short term.
- ·19 t sittenWill we close in the green today? 😁·17 t sittenThanks for your reply. I started here a few days ago so I didn't quite realize it kept running😏·17 t sittenRead along and separate the wheat from the chaff – then the rest is up to you 😉
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 432 651
Myynti
Määrä
2 429 737
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 125 | - | - | ||
| 689 | - | - | ||
| 16 | - | - | ||
| 228 | - | - | ||
| 449 | - | - |
Ylin
377,65VWAP
Alin
366,45VaihtoMäärä
2 264,2 6 104 675
VWAP
Ylin
377,65Alin
366,45VaihtoMäärä
2 264,2 6 104 675
Välittäjätilasto
Dataa ei löytynyt